TSC2 and tuberous sclerosis: Our finding that simultaneous inhibition of the lysosome and endosomal trafficking inhibits the proliferation of TSC2-deficient cells provides a novel potential therapeutic avenue for the treatment of TSC and other diseases associated with mTORC1 hyperactivation, including lymphangioleiomyomatosis (LAM) and the majority of human malignancies.